×

Homogenous antibody drug conjugates via enzymatic methods

  • US 10,471,037 B2
  • Filed: 05/22/2018
  • Issued: 11/12/2019
  • Est. Priority Date: 06/12/2014
  • Status: Active Grant
First Claim
Patent Images

1. An engineered transglutaminase comprising an amino acid sequence having at least about 80% identity to SEQ ID NO:

  • 16, wherein the engineered transglutaminase comprises one or more mutations selected from the group consisting of;

    deletion of D1-E4;

    deletion of P244-P247;

    deletion of N282-L285;

    substitution of H279-A287 with a G; and

    substitution of A280-H289 with a G.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×